Corneal edema Market: Epidemiology, Therapies, Companies, DelveInsight | Emmetrope Ophthalmics LLC ("Emmecell"), Trefoil Therapeutics, D. Western Therapeutics Institute (DWTI), Kowa Ltd., Santen Pharmaceutical, Actual Eyes

Corneal edema emerging therapies, such as EO2002, TTHX1114, and others, are expected to boost the Corneal edema Market in the upcoming years.

DelveInsight has launched a new report on "Corneal edema - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Corneal edema, historical and forecasted epidemiology as well as the Corneal edema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Corneal edema market report @ https://www.delveinsight.com/report-store/corneal-edema-us-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Corneal edema Market Report:

The Corneal Edema market is expected to experience steady growth throughout the forecast period (2023-2034). In the US, the market is anticipated to expand due to the introduction of new therapies. In 2022, the US market primarily consisted of corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), and other treatments, generating around USD 489 million.
DelveInsight's analysts estimate that the total diagnosed prevalent cases of Corneal Edema in the US were approximately 1,149,967 in 2022, with a continued increase expected during the forecast period (2023-2034).
The overall market for Corneal Edema treatments is projected to grow as new and effective therapies, such as EO2002, become available.
Corneal edema is the swelling of the cornea, the clear, dome-shaped outer layer of the eye that protects the iris and pupil. The cornea plays a crucial role in focusing light onto the retina for clear vision. When fluid accumulates excessively in the cornea, it causes the vision to become blurry or cloudy.
Corneal edema can be caused by various factors, each leading to the buildup of fluid in the cornea, resulting in a foggy or hazy visual appearance. A common cause is endothelial dysfunction, where the cells lining the inner surface of the cornea, known as the endothelium, are damaged. Conditions like Fuchs' dystrophy or complications from eye surgery can impair these cells' ability to regulate fluid, resulting in edema. Eye trauma or injury can also trigger corneal swelling, while inflammatory conditions like uveitis can worsen the edema by causing eye inflammation.
Symptoms of corneal edema include blurred or cloudy vision, as the accumulation of fluid scatters light. This can significantly reduce visual acuity, making it difficult to see fine details. Another common symptom is light sensitivity, known as photophobia.
According to DelveInsight's estimates, the total number of diagnosed prevalent cases of Corneal Edema in the United States was around 1,149,967 in 2022, with expectations for this number to rise during the forecast period.
In April 2025, the FDA granted Fast Track designation to urcosimod (formerly OK-101) for the treatment of neuropathic corneal pain, a condition with no current FDA-approved treatments. Urcosimod is a lipid-conjugated chemerin peptide agonist targeting the ChemR23 receptor, showing positive results in a Phase 2 trial for dry eye disease.
In December 2024, Glaukos submitted a New Drug Application (NDA) to the FDA for Epioxa, a non-invasive corneal cross-linking therapy that does not require epithelial removal. If approved, Epioxa would be the first FDA-approved therapy of its kind, offering a less invasive option for treating corneal ectasia.
In June 2024, the FDA granted both Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations to AURN001, an allogeneic cell therapy for treating corneal edema secondary to corneal endothelial disease. This combination therapy includes allogeneic human corneal endothelial cells (neltependocel) and a rho kinase inhibitor (Y-27632), administered as a one-time procedure into the anterior chamber of the eye. The Phase 1/2 CLARA trial demonstrated significant improvements in visual acuity, with the high-dose group showing a statistically significant three-line improvement compared to controls.
Key Corneal edema companies such as Emmetrope Ophthalmics LLC ("Emmecell"), Trefoil Therapeutics, D. Western Therapeutics Institute (DWTI), Kowa Ltd., Santen Pharmaceutical, Actual Eyes, and others are evaluating new drugs for Corneal edema to improve the treatment landscape.
Promising Corneal edema therapies include EO2002, TTHX1114, and others.

Corneal edema Overview

Myositis refers to inflammation of the muscles and is commonly linked with a group of inflammatory muscle diseases, including polymyositis, dermatomyositis, cancer-associated myositis, juvenile dermatomyositis, overlap myositis, and inclusion body myositis (IBM). While *myositis* specifically involves inflammation, *myopathy* is a broader term encompassing any disease or disorder of the muscles, including but not limited to myositis.

This rare condition can impact not only the muscles but also various other organs, often resulting in significant reductions in quality of life. According to the American College of Rheumatology, inflammatory myopathies are autoimmune diseases in which the immune system mistakenly attacks healthy muscle tissue. Dermatomyositis and polymyositis are the most frequently occurring types within this group.

Corneal edema Market Outlook

The current treatment approach for corneal edema is customized based on the underlying cause and severity of the condition. Initial management typically includes the use of hypertonic saline solutions and topical steroids to reduce inflammation and remove excess fluid from the cornea. Hyperosmotic agents, such as oral or topical carbonic anhydrase inhibitors, may also be used. Bandage contact lenses can help improve vision by smoothing the corneal surface. In cases where the corneal endothelium is significantly damaged, surgical options like corneal transplantation, including Descemet's Stripping Endothelial Keratoplasty (DSEK) or Descemet's Membrane Endothelial Keratoplasty (DMEK), may be necessary. Laser treatments, such as Selective Laser Trabeculoplasty (SLT), might be considered for cases linked to secondary glaucoma. Additionally, managing the underlying conditions causing the edema and using artificial tears for lubrication can be part of the overall treatment plan. This approach is evolving, with ongoing research into innovative therapies, such as investigational drugs like TTHX1114 and sirolimus, which may expand treatment options for corneal edema in the future.

Discover how the Corneal edema market is rising in the coming years @ https://www.delveinsight.com/sample-request/corneal-edema-us-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Corneal edema Emerging Drugs
EO2002: Emmetrope Ophthalmics LLC
TTHX1114: Trefoil Therapeutics

Scope of the Corneal edema Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Corneal edema Companies: Emmetrope Ophthalmics LLC ("Emmecell"), Trefoil Therapeutics, D. Western Therapeutics Institute (DWTI), Kowa Ltd., Santen Pharmaceutical, Actual Eyes, and others
Key Corneal edema Therapies: EO2002, TTHX1114, and others
Corneal edema Therapeutic Assessment: Corneal edema current marketed and Corneal edema emerging therapies
Corneal edema Market Dynamics: Corneal edema market drivers and Corneal edema market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Corneal edema Unmet Needs, KOL's views, Analyst's views, Corneal edema Market Access and Reimbursement

To know what's more in our Corneal edema report, visit https://www.delveinsight.com/report-store/corneal-edema-us-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Corneal edema Market Report:
Corneal edema market report covers a descriptive overview and comprehensive insight of the Corneal edema Epidemiology and Corneal edema market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Corneal edema market report provides insights into the current and emerging therapies.
The Corneal edema market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Corneal edema market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Corneal edema market.

Got queries? Click here to know more about the Corneal edema market Landscape https://www.delveinsight.com/sample-request/corneal-edema-us-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Corneal edema Patient Share (%) Overview at a Glance
5. Corneal edema Market Overview at a Glance
6. Corneal edema Disease Background and Overview
7. Corneal edema Epidemiology and Patient Population
8. Country-Specific Patient Population of Corneal edema
9. Corneal edema Current Treatment and Medical Practices
10. Unmet Needs
11. Corneal edema Emerging Therapies
12. Corneal edema Market Outlook
13. Country-Wise Corneal edema Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Corneal edema Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Corneal edema Market Outlook 2034 https://www.delveinsight.com/report-store/corneal-edema-us-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Corneal edema Pipeline Insights, DelveInsight

"Corneal edema Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Corneal edema market. A detailed picture of the Corneal edema pipeline landscape is provided, which includes the disease overview and Corneal edema treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.